Research Article
Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases
Table 2
Clinicopathological parameters of thyroid cancer patients.
| | Parameters | N (%) | Parameters | N (%) |
| | Age | | Multifocality | | | 45 years | 17 (53.10) | Present | 14 (43.70) | | 45 years | 15 (46.90) | Absent | 18 (56.30) |
| | Gender | | Bilaterality | | | Male | 09 (28.10) | Unilateral | 23 (71.90) | | Female | 23 (71.90) | Bilateral | 09 (28.10) |
| | Tumor size | | Haemorrhagic area | | | T1 + T2 | 16 (50.00) | Present | 07 (21.90) | | T3 + T4 | 16 (50.00) | Absent | 25 (78.10) |
| | Lymph node metastasis | | Necrosis | | | Present | 18 (56.30) | Present | 03 (9.40) | | Absent | 14 (43.70) | Absent | 29 (90.60) |
| | Distant metastasis | | Calcification | | | Present | 21 (65.60) | Present | 19 (59.40) | | Absent | 11 (34.30) | Absent | 13 (40.60) |
| | Stage | | Sclerosis | | | Early stage (Stage I & II) | 15 (46.90) | Present | 04 (12.50) | | Advanced stage (Stage III & IV) | 17 (53.10) | Absent | 28 (87.50) |
| | Lymphatic permeation | | Extrathyroidal extension | | | Present | 04 (12.50) | Present | 13 (40.60) | | Absent | 28 (87.50) | Absent | 19 (59.40) |
| | Vascular permeation | | Fibrosis | | | Present | 08 (25.00) | Present | 08 (25.00) | | Absent | 24 (75.00) | Absent | 24 (75.00) |
| | Capsular invasion | | Inflammation | | | Present | 13 (40.60) | Present | 14 (43.70) | | Absent | 19 (59.40) | Absent | 18 (56.30) |
| | Encapsulation | | Differentiation | | | Well-encapsulated | 27 (84.40) | Well | 22 (68.75) | | Not encapsulated | 05 (15.60) | Moderate/Poor | 10 (31.25) |
|
|
